Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22502277 | 1.00 | LMNA (0.49) | LMNACNR1TACR3CYP3A4CYP2C9 | |
| SCHEMBL10332571 | 0.88 | LMNA (0.53) | LMNACNR1TACR3CYP3A4CYP2C9 | |
| SCHEMBL13707805 | 0.84 | TACR3 (0.46) | LMNACNR1TACR3CYP3A4CYP2C9 | |
| SCHEMBL19658733 | 0.84 | LMNA (0.46) | LMNACNR1TACR3CYP3A4CYP2C9 | |
| SCHEMBL12880512 | 0.84 | LMNA (0.46) | LMNACNR1TACR3CYP3A4CYP2C9 | |
| SCHEMBL19658438 | 0.84 | LMNA (0.46) | LMNACNR1TACR3CYP3A4CYP2C9 | |
| SCHEMBL10966252 | 0.84 | TACR3 (0.49) | LMNACNR1TACR3CYP3A4CYP2C9 | |
| Tert-Butyl Formate SCHEMBL28841632 | 0.83 | CNR1 (0.41) | LMNACNR1TACR3CYP3A4CYP2C9 | |
| SCHEMBL8750970 | 0.83 | FPR2 (0.54) | LMNATACR3MAPK1CA1CA2 | |
| SCHEMBL16163822 | 0.83 | CYP2D6 (0.44) | LMNAMAPK1CTSDCNR2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-07-13 | — | — | US | claimed |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS., LTD. | 2021-04-22 | — | — | US | claimed |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-01-12 | — | — | US | claimed |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2020-02-13 | — | — | US | claimed |
| US-9833432-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-12-05 | — | — | US | claimed |
| EP-3110792-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK Biopharmaceuticals Co., Ltd. (KR) | 2017-01-04 | — | — | EP | claimed |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. | 2016-10-20 | — | — | US | claimed |
| US-9403761-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-08-02 | — | — | US | claimed |
| WO-2015130121-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | WO | claimed |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | US | claimed |
| EP-4395763-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME THERAPEUTICS (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230115176-A1 | Complement Modulators and Related Methods | RA PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| WO-2023034944-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME THERAPEUTICS (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-3947352-A1 | COMPLEMENT MODULATORS AND RELATED METHODS | RA Pharmaceuticals, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. | 2016-10-20 | — | — | US | disclosed |
| US-9403761-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-08-02 | — | — | US | disclosed |
| WO-2015130121-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | WO | disclosed |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | US | disclosed |
| WO-2008074035-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115176-A1 | Complement Modulators and Related Methods | C5, C9, C1QBP | LMNA 1461/4885CNR1 1914/4885TACR3 1698/4885 |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | LMNA 4283/4885CNR1 54/4885TACR3 354/4885 |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SLC6A3, SLC6A2, SLC6A4 | LMNA 4283/4885CNR1 54/4885TACR3 354/4885 |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | LMNA 4283/4885CNR1 54/4885TACR3 354/4885 |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | LMNA 4283/4885CNR1 54/4885TACR3 354/4885 |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | LMNA 4283/4885CNR1 54/4885TACR3 354/4885 |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | LMNA 4283/4885CNR1 54/4885TACR3 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.